A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

M. A. Nauck; S. Duran; D. Kim; D. Johns; J. Northrup; A. Festa; R. Brodows; M. Trautmann

首页> 外文期刊>Diabetologia >A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

【24h】

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

机译：磺脲类和二甲双胍亚最佳控制的2型糖尿病患者每日两次艾塞那肽和双相门冬胰岛素的比较：一项非劣效性研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The aim of this 52-week, open-label, non-inferiority trial was to compare the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart.

机译：这项为期52周的开放性，非劣效性试验的目的是比较艾塞那肽（一种降钙素模拟物）与双相门冬胰岛素的安全性和有效性。

著录项

来源
《Diabetologia 》 |2007年第2期| 259-267| 共9页
作者
M. A. Nauck; S. Duran; D. Kim; D. Johns; J. Northrup; A. Festa; R. Brodows; M. Trautmann;
展开▼
作者单位

Diabetes Center Kirchberg 21 37431 Bad Lauterberg im Harz Germany;

Department of Endocrinology Valme Hospital Seville Spain;

Amylin Pharmaceuticals San Diego CA USA;

Lilly Research Laboratories Indianapolis IN USA;

Lilly Research Laboratories Indianapolis IN USA;

Lilly Research Laboratories Vienna Austria;

Lilly Research Laboratories Indianapolis IN USA;

Lilly Research Laboratories Hamburg Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Biphasic insulin aspart; Exenatide; Incretin mimetic; Non-inferiority; Type 2 diabetes; Weight reduction;

机译：天冬氨酸双相;艾塞那肽;肠降血糖素模拟;非自卑;2型糖尿病;减重;

相似文献

外文文献
中文文献
专利

1. Response to comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267 [J] . M. A. Nauck, M. Trautman, R. Brodows, Diabetologia . 2007 ,第7期

机译：对评论的回应：Nauck MA，Duran S，Kim D等人（2007年）对磺脲类和二甲双胍亚最佳控制的2型糖尿病患者每日两次艾塞那肽和双相门冬胰岛素的比较：一项非劣效性研究。糖尿病50：259–267
2. Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267 [J] . P. D. Home Diabetologia . 2007 ,第7期

机译：评论：Nauck MA，Duran S，Kim D等人（2007年）对磺脲类和二甲双胍亚最佳控制的2型糖尿病患者每天两次艾塞那肽和双相门冬胰岛素的比较：一项非劣效性研究。糖尿病50：259–267
3. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride. [J] . stigma of screening suffering from screening and impact of screening on patients independence. The internal consistency of each of the above subscales was good with Cronbachs alpha ranging from 0.58 0.85. CONCLUSION: The PRISM PC questionnaire captu, Attitude to Health, Cross Sectional Studies Diabetes research and clinical practice . 2009 ,第1期

机译：磺脲类药物对转换为胰岛素治疗的影响（每日两次双天冬胰岛素30）：比较2型糖尿病患者在亚最大格列美脲控制不佳的情况下每天两次两次天冬胰岛素30含或不含格列美脲的比较。
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter Open-Label Randomized Trial [O] . Li Wang, Xiangyang Liu, Wenjuan Yang, 2020

机译：用二甲双胍单药治疗的2型糖尿病患者艾塞那肽和双相胰岛素Aspart 30在中国参与者中的血糖变异性比较：多中心开放标签随机试验
7. Response to comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267 [O] . M. A. Nauck, M. Trautman, R. Brodows, 2007

机译：对评论的回应：Nauck MA，Duran S，Kim D等人（2007）对2型糖尿病患者的两次exenatide和双相胰岛素Aspart进行比较，患有磺酰脲和二甲双胍的2型糖尿病：一种非劣级研究。糖尿病症50：259-267

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

摘要

著录项

相似文献

相关主题

期刊订阅